-
Sources of funding for pharmaceutical research has come under scrutiny in the last decade as academic and government sources of funding have become increasingly scarce and the pharmaceutical industry has become the main source of research dollars. But the issue of objectivity has been raised, and some have even suggested that negative studies, that is studies that show a drug in an unfavorable light, may never be published.
-
-
Sasser H. Faltering promise: Vitamin E and heart disease. Altern Med Alert 2004;7(9):101-104.
-
A new portrait of CAM use in the United States. Altern Med Alert 2004;7(9):S1-S2.
-
-
For unvaccinated or high-risk vaccinated patients during the influenza season, empirical oseltamivir treatment is cost-effective. For other patients, rapid diagnostic testing followed by treatment with oseltamivir is cost-effective. Empirical amantadine treatment offers a low-cost alternative if patients cannot afford oseltamivir.
-
As determined by process-of-care measurement, adverse event occurrence, and patient satisfaction, quality of care is compromised by infection control procedures.
-
The FDA has approved the first once-daily, quaternary ammonium, anticholinergic bronchodilator for the treatment of chronic obstructive pulmonary disease.
-
Risk of Adenocarcinoma in Barretts Esophagus; Long-Term Effect of Doxazosin, Finasteride, and Combination for BPH; Once Daily Valacyclovir to Reduce Herpes Transmission
-